Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Immunic, Inc. before investing.

In this article, we go over a few key elements for understanding Immunic, Inc.’s stock price such as:

• Immunic, Inc.’s current stock price and volume
• Why Immunic, Inc.’s stock price changed recently
• Upgrades and downgrades for IMUX from analysts
• IMUX’s stock price momentum as measured by its relative strength

About Immunic, Inc. (IMUX)

Before we jump into Immunic, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Want to learn more about Immunic, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Immunic, Inc..

Immunic, Inc.’s Stock Price as of Market Close

As of January 15, 2026, 4:00 PM, CST, Immunic, Inc.’s stock price was $0.639.

Immunic, Inc. is down 0.61% from its previous closing price of $0.643.

During the last market session, Immunic, Inc.’s stock traded between $0.626 and $0.680. Currently, there are approximately 193.90 million shares outstanding for Immunic, Inc..

Immunic, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Immunic, Inc. Stock Price History

Immunic, Inc.’s (IMUX) price is currently up 19.71% so far this month.

During the month of January, Immunic, Inc.’s stock price has reached a high of $0.720 and a low of $0.509.

Over the last year, Immunic, Inc. has hit prices as high as $1.390 and as low as $0.506. Year to date, Immunic, Inc.’s stock is up 19.71%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Immunic, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of January 15, 2026,, no analysts have changed their rating of Immunic, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Immunic, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Immunic, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Immunic, Inc. (IMUX) by visiting AAII Stock Evaluator.

Relative Price Strength of Immunic, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 15, 2026, Immunic, Inc. has a weighted four-quarter relative price strength of -15.80%, which translates to a Momentum Score of 13 and is considered to be Very Weak.

Want to learn more about how Immunic, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Immunic, Inc. Stock Price: Bottom Line

As of January 15, 2026, Immunic, Inc.’s stock price is $0.639, which is down 0.61% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Immunic, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.